Literature DB >> 27195752

Lung Capillary Stress Failure and Arteriolar Remodelling in Pulmonary Hypertension Associated with Left Heart Disease (Group 2 PH).

Nour R Dayeh1, Jonathan Ledoux2, Jocelyn Dupuis3.   

Abstract

Left heart diseases (LHD) represent the most prevalent cause of pulmonary hypertension (PH), yet there are still no approved therapies that selectively target the pulmonary circulation in LHD. The increase in pulmonary capillary pressure due to LHD is a triggering event leading to physical and biological alterations of the pulmonary circulation. Acutely, mechanosensitive endothelial dysfunction and increased capillary permeability combined with reduced fluid resorption lead to the development of interstitial and alveolar oedema. From repeated cycles of such capillary stress failure originate more profound changes with pulmonary endothelial dysfunction causing increased basal and reactive pulmonary vascular tone. This contributes to pulmonary vascular remodelling with increased arterial wall thickness, but most prominently, to alveolar wall remodelling characterized by myofibroblasts proliferation with collagen and interstitial matrix deposition. Although protective against acute pulmonary oedema, alveolar wall thickening becomes maladaptive and is responsible for the development of a restrictive lung syndrome and impaired gas exchanges contributing to shortness of breath and PH. Increasing awareness of these processes is unraveling novel pathophysiologic processes that could represent selective therapeutic targets. Thus, the roles of caveolins, of the intermediate myofilament nestin and of endothelial calcium dyshomeostasis were recently evaluated in pre-clinical models. The pathophysiology of PH due to LHD (group II PH) is distinctive from other groups of PH. Therefore, therapies targeting PH due to LHD must be evaluated in that context.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Heart failure; Lung remodelling; Pathophysiology; Pulmonary hypertension; Vascular endothelium

Mesh:

Year:  2016        PMID: 27195752     DOI: 10.1016/j.pcad.2016.05.002

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN: 0033-0620            Impact factor:   8.194


  9 in total

Review 1.  Insights into the pulmonary vascular complications of heart failure with preserved ejection fraction.

Authors:  Yen-Chun Lai; Longfei Wang; Mark T Gladwin
Journal:  J Physiol       Date:  2018-12-30       Impact factor: 5.182

Review 2.  Understanding the Pathobiology of Pulmonary Hypertension Due to Left Heart Disease.

Authors:  Jessica H Huston; Sanjiv J Shah
Journal:  Circ Res       Date:  2022-04-28       Impact factor: 23.213

3.  Pulmonary Arterial Hypertension Specific Therapy in Patients with Combined Post- and Precapillary Pulmonary Hypertension.

Authors:  Hassan Alfraidi; Sultan Qanash; Zoheir Bshouty
Journal:  Pulm Med       Date:  2018-03-01

Review 4.  The Biological Bases of Group 2 Pulmonary Hypertension.

Authors:  Ana I Fernández; Raquel Yotti; Ana González-Mansilla; Teresa Mombiela; Enrique Gutiérrez-Ibanes; Candelas Pérez Del Villar; Paula Navas-Tejedor; Christian Chazo; Pablo Martínez-Legazpi; Francisco Fernández-Avilés; Javier Bermejo
Journal:  Int J Mol Sci       Date:  2019-11-23       Impact factor: 5.923

Review 5.  Animal models of pulmonary hypertension due to left heart disease.

Authors:  Shao-Fei Liu; Yi Yan
Journal:  Animal Model Exp Med       Date:  2022-02-09

6.  Epidemiological profile and obstetric outcomes of patients with peripartum congestive heart failure in Taiwan: a retrospective nationwide study.

Authors:  Ying-Jen Chang; Chung-Han Ho; Jen-Yin Chen; Ming-Ping Wu; Chia-Hung Yu; Jhi-Joung Wang; Chia-Ming Chen; Chin-Chen Chu
Journal:  BMC Pregnancy Childbirth       Date:  2017-09-12       Impact factor: 3.007

7.  Rho-Kinase Inhibition Ameliorates Dasatinib-Induced Endothelial Dysfunction and Pulmonary Hypertension.

Authors:  Csilla Fazakas; Chandran Nagaraj; Diana Zabini; Attila G Végh; Leigh M Marsh; Imola Wilhelm; István A Krizbai; Horst Olschewski; Andrea Olschewski; Zoltán Bálint
Journal:  Front Physiol       Date:  2018-05-15       Impact factor: 4.566

8.  Practice patterns of pulmonary hypertension secondary to left heart disease among pediatric pulmonary hypertension providers.

Authors:  Hythem Nawaytou; Jeffrey R Fineman; Shahin Moledina; Dunbar Ivy; Steven H Abman; Maria J Del Cerro
Journal:  Pulm Circ       Date:  2021-02-09       Impact factor: 3.017

Review 9.  Nestin-Expressing Cells in the Lung: The Bad and the Good Parts.

Authors:  Gilberto Jaramillo-Rangel; María-de-Lourdes Chávez-Briones; Adriana Ancer-Arellano; Marta Ortega-Martínez
Journal:  Cells       Date:  2021-12-04       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.